Μελέτες

20 Aug

Posted at 10:29h in Μελέτες by

ΑΝΔΡΕΑΣ ΠΙΤΤΑΡΑΣ MD Ο Κιρκάδειος τύπος διακύμανσης της Αρτηριακής πίεσης Κλινικές και θεραπευτικές επιπτώσεις Blood pressure varies widely over 24 hours, and this may contribute to the fact that acute cardiovascular events peak in the morning hours. Reducing morning BP may prevent these occurrences, and so identifying...

20 Aug

Posted at 10:28h in Μελέτες by

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the...

20 Aug

Posted at 10:27h in Μελέτες by

STAR determined whether glycaemic control was maintained to a greater degree by an RAS inhibitor/non-DHP CCB than an RAS inhibitor/thiazide diuretic in hypertensive patients with metabolic syndrome. STAR: rationale Metabolic syndrome associated with increased risk of new-onset diabetes and cardiovascular disease. Antihypertensive therapy may be beneficial in reducing...

20 Aug

Posted at 10:26h in Μελέτες by

TROPHY - hypothesis The TRial Of Preventing HYpertension (TROPHY) is an investigator-initiated trial to examine whether early treatment of high-normal blood pressure values (according to JNC VI) with candesartan would prevent or postpone the development of stage 1 hypertension. TROPHY - objectives Primary: to determine whether treatment with...

20 Aug

Posted at 10:22h in Μελέτες by

Athanasios J. Manolisa, John L. Reidb, Dick de Zeeuwc, Michael B. Murphyd, Elke Seewaldt-Beckere and Ju¨ rgen Ko¨ sterf on behalf  of the ARAMIS Study Group Objective: To identify telmisartan doses that are more effective than placebo and non-inferior to hydrochlorothiazide (HCTZ) 12.5 mg, and are well...